<SEC-DOCUMENT>0001206774-14-002139.txt : 20140721
<SEC-HEADER>0001206774-14-002139.hdr.sgml : 20140721
<ACCEPTANCE-DATETIME>20140721153836
ACCESSION NUMBER:		0001206774-14-002139
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20140721
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20140721
DATE AS OF CHANGE:		20140721

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		14984683

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>geron_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>
<P align=center><B><FONT face="Times New Roman" size=2>UNITED STATES
<BR></FONT></B><B><FONT face="Times New Roman" size=2>SECURITIES AND EXCHANGE
COMMISSION <BR>WASHINGTON, D.C. 20549 <BR>___________<BR></FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>FORM 8-K</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>CURRENT
REPORT<BR></FONT></B><B><FONT face="Times New Roman" size=2>PURSUANT TO SECTION
13 OR 15(d) OF THE <BR>SECURITIES EXCHANGE ACT OF 1934</FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P align=center><FONT face="Times New Roman" size=2>Date of Report (Date of
earliest event reported):</FONT> <B><FONT face="Times New Roman" size=2>July 21,
2014</FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>GERON
CORPORATION</FONT></B> <FONT face="Times New Roman" size=2><BR></FONT><FONT face="Times New Roman" size=2>(Exact name of registrant as specified in its
charter)</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>Delaware</FONT></B></TD>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>0-20859</FONT></B></TD>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>75-2287752</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(State or other jurisdiction</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(Commission File Number)</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(IRS
      Employer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>of
      incorporation)</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>Identification
No.)</FONT></TD></TR></TABLE><BR>
<P align=center><B><FONT face="Times New Roman" size=2>149 COMMONWEALTH DRIVE,
SUITE 2070 <BR>MENLO PARK, CALIFORNIA 94025 <BR></FONT></B><FONT face="Times New Roman" size=2>(Address of principal executive offices, including
zip code)</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>(650)
473-7700<BR></FONT></B><FONT face="Times New Roman" size=2>(Registrant&#146;s
telephone number, including area code)</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>N/A <BR></FONT></B><FONT face="Times New Roman" size=2>(Former name or former address, if changed since
last report)</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:</FONT></P>
<P align=left>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" width="1%"><FONT face=wingdings size=2>o</FONT></TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" width="98%">
      <P><FONT face="Times New Roman" size=2>Written communications pursuant to
      Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P></TD></TR>
  <TR>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" width="1%"><FONT face=Wingdings size=2>o</FONT></TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" width="1%"></TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" width="98%">
      <P><FONT face="Times New Roman" size=2>Soliciting material pursuant to
      Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P></TD></TR>
  <TR>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" width="1%"><FONT face=Wingdings size=2>o</FONT></TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" width="1%"></TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" width="98%">
      <P><FONT face="Times New Roman" size=2>Pre-commencement communications
      pursuant to Rule 14d-2(b) under the Exchange Act (17 </FONT><FONT face="Times New Roman" size=2>CFR 240.14d-2(b))</FONT></P></TD></TR>
  <TR>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" width="1%"><FONT face=Wingdings size=2>o</FONT></TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" width="1%"></TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" width="98%">
      <P><FONT face="Times New Roman" size=2>Pre-commencement communications
      pursuant to Rule 13e-4(c) under the Exchange Act (17 </FONT><FONT face="Times New Roman" size=2>CFR
240.13e-4(c))</FONT></P></TD></TR></TABLE></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><FONT face="Times New Roman" size=2>Item 8.01. Other Events.
</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On May 9, 2014, Geron Corporation
(the &#147;Company&#148; or &#147;Geron&#148;) announced the record date (the &#147;Record Date&#148;) for the
distribution to Geron stockholders of the Asterias Series A common stock that
Geron received in the previously announced transaction to divest Geron&#146;s human
embryonic stem cell assets and autologous cellular immunotherapy program to
Asterias Biotherapeutics, Inc. (formerly known as BioTime Acquisition
Corporation) (&#147;Asterias&#148;). The Record Date set by the Company&#146;s Board of
Directors was May 28, 2014.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As previously announced, under the
terms of the Asset Contribution Agreement with BioTime, Inc. (NYSE: BTX) and
Asterias, dated January 4, 2013 (the &#147;Agreement&#148;), which closed on October 1,
2013, Asterias issued to Geron 6,537,779 shares of Asterias Series A common
stock as consideration for Geron&#146;s contribution to Asterias of its human
embryonic stem cell assets and autologous cellular immunotherapy program. Under
the terms of the Agreement and subject to applicable law, Geron is contractually
obligated to distribute all of the shares of Asterias Series A common stock to
Geron stockholders of record as of the Record Date on a pro rata basis (the
&#147;Series A Distribution&#148;), other than with respect to fractional shares and
shares that would otherwise be distributed to Geron stockholders residing in
certain excluded jurisdictions, which shares, as required by the Agreement, will
be sold for cash at prevailing market prices with the net cash proceeds
therefrom distributed ratably to Geron stockholders who would otherwise be
entitled to receive such shares. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Nasdaq Stock Market has set July
22, 2014 as the ex-dividend date (the &#147;Ex-Dividend Date&#148;) for the Series A
Distribution. In order to receive shares of Asterias Series A common stock or
cash in the Series A Distribution, Geron stockholders as of the Record Date must
hold their shares of Geron common stock through the Ex-Dividend Date.
</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the number of shares of
Geron common stock outstanding as of the Record Date (156,924,100 shares), for
each share of Geron common stock held by a Geron stockholder, such Geron
stockholder will receive approximately 0.0417 of a share of Asterias Series A
common stock in the Series A Distribution, or cash in lieu thereof as described
above. This ratio equates to one whole share of Asterias Series A common stock
for approximately every 24 shares of Geron common stock. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asterias has been advised that
trading of Asterias Series A common stock is expected to begin on a &#147;when
issued&#148; basis on July 21, 2014 on the OTCBB under the ticker symbol ASTYV.
&#147;When-issued&#148; trading refers to a sale or purchase made conditionally because
the security has been authorized, but not yet issued. All trades that take place
on a &#147;when issued&#148; basis are expected to settle three business days after the
completion of the Series A Distribution, which is expected to occur within the
next one to several weeks. There can be no assurance that an active public market for either the Asterias Series A common stock or BioTime Warrants (as defined below) will ever develop. Geron stockholders are cautioned that any value that Geron stockholders may ascribe to the Asterias Series A common stock or the related BioTime Warrants is highly speculative.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Geron is distributing the shares of
Asterias Series A common stock pursuant to a registration statement on Form S-1, File No. 333-187706 (the &#147;Registration Statement&#148;), filed by Asterias under
the U.S. Securities Act of 1933, as amended. The Registration Statement and the
prospectus included therein (the &#147;Prospectus&#148;) contain important information
about Asterias, the Asterias Series A common stock and the Series A
Distribution. As described therein, Asterias is a newly organized, development
stage company in the start-up phase, and has only recently commenced its primary
product development programs. Geron stockholders should read the Registration
Statement and the Prospectus carefully, including the Risk Factors section of
the Prospectus for further information about Asterias and the risks of owning
Asterias Series A common stock. The Registration Statement and a final
Prospectus, which may be amended from time
to time, are available at the website maintained by the Securities and Exchange
Commission at http://www.sec.gov. A copy of the Prospectus may be obtained from
Asterias upon request to their Chief Financial Officer at 230 Constitution
Drive, Menlo Park, CA 94025 or contacting their investor relations
representative at InvestorRelations@asteriasbio.com.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>1 </FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Following completion of the Series A
Distribution by Geron, Asterias is contractually obligated under the Agreement
to distribute on a pro rata basis to the holders of Asterias Series A common
stock five-year warrants to purchase eight million shares of BioTime common
stock at an exercise price of $5.00 per share (the &#147;BioTime Warrants&#148;). The
BioTime Warrants were issued to Asterias by BioTime upon the close of the asset
contribution transaction pursuant to the Agreement. </FONT></P>

<P STYLE="text-align: center"><B><FONT face="Times New Roman" size=2>Use of Forward-Looking
Statements </FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P align=left><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Except for the historical information
contained herein, this Current Report on Form 8-K contains  forward-looking statements made pursuant to the "safe
harbor" provisions of the  Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in
this Current Report on Form 8-K regarding: (a) any value to Geron  stockholders of the Asterias Series A common stock and the
BioTime Warrants; (b)  Geron&#146;s plans or expectations for the timing and completion of the Series A Distribution and the
BioTime Warrants to be distributed as contemplated by the Asset Contribution  Agreement; (c) Geron&#146;s payment of cash in
lieu of fractional and other shares; and  (d) ability to trade the Asterias Series A
common stock upon the completion of the Series A Distribution, constitute forward-looking statements. These statements involve risks and uncertainties that can
cause actual results to differ materially from those in  such forward-looking statements. These risks and uncertainties,
include, without  limitation: (i) the possibility that Geron stockholders may realize little or no  value from the Asterias
Series A common stock and/or the BioTime Warrants; (ii)  the possibility that Geron stockholders may incur tax liabilities,
but be unable  to realize value from any Asterias Series A common stock distributed by Geron  and/or the BioTime Warrants to
be distributed by Asterias; (iii) the potential  inability of Geron to complete the Series A </FONT><FONT face="Times New Roman" size=2>Distribution
or of Asterias to distribute the BioTime Warrants, as well  as the payment of cash in lieu of fractional and other shares, in
a timely  manner or at all, including as a result of the failure of BioTime and/or  Asterias to maintain required federal and
state registrations and qualifications  necessary to enable the Series A Distribution, the BioTime Warrants distribution, and
related transactions; (iv) that the U.S. federal income tax  laws are complex and subject to change at any time, possibly
with retroactive  effect, and the U.S. federal income tax treatment for the receipt of Asterias  Series A common stock are
highly dependent on a holder&#146;s particular situation;  (v) the possibility of litigation that could arise as a result of
or in  connection with the Series A </FONT><FONT face="Times New Roman" size=2>Distribution, the BioTime Warrants
distribution and related transactions,  as well as the asset contribution transaction itself, including litigation arising
from the possibility that Geron stockholders may realize little or no  value from the Asterias Series A common stock and/or
the BioTime Warrants; and  (vi) that there is no active public market for the Asterias Series A common  stock, nor any
existing public market for the BioTime Warrants, nor may any  active or existing public market for such securities ever
develop. Additional  information and factors that could cause  actual results to differ materially from those in the
forward-looking statements  are contained in Geron&#146;s periodic reports filed with the SEC under the heading &#147;Risk
Factors,&#148; including Geron&#146;s quarterly report on Form 10-Q for the quarter  ended March 31, 2014. Undue reliance
should not be placed on forward-looking  statements, which speak only as of the date they are made, and the facts and
assumptions underlying the forward-looking statements may change. Except as  required by law, Geron disclaims any obligation
to update these forward-looking  statements to reflect future information, events or circumstances.  </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>2 </FONT></P>
<HR align=center width="100%" noShade SIZE=2>


<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>SIGNATURE </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="48%"></TD>
    <TD noWrap align=left width="52%" colSpan=2><FONT face="Times New Roman" size=2>GERON CORPORATION</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="48%"><FONT face="Times New Roman" size=2>Date: July 21, 2014</FONT></TD>
    <TD noWrap align=left width="1%"><FONT size=2 face="Times New Roman">By: </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="51%"><FONT face="Times New Roman" size=2>&nbsp; /s/ Olivia Bloom</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="48%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="51%"><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="48%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="51%"><FONT face="Times New Roman" size=2>Executive Vice President, Finance,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="48%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="51%"><FONT face="Times New Roman" size=2>Chief Financial
Officer</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>3 </FONT></P>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
